Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction
| Basic data | |
|---|---|
| OCA1. Surname awarded to the assessed person | Kyselovič |
| OCA2. Name awarded to the assessed person | Ján |
| OCA3. Degrees awarded to the assessed person | Prof. , Pharm.D., CSc. |
| OCA4. Hyperlink to the entry of the person in the Register of university staff | https://www.portalvs.sk/regzam/detail/3738 |
| OCA5. Area of assessment | study programme pharmacy (joint study programme) · I. + II. degree |
| OCA6. Category of the research/artistic/other output | scientific output |
| OCA7. Year of publication of the research/artistic/other output | 2019 |
| OCA8. ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) | 128712 |
| OCA9. Hyperlink to the record in CRPA or CRAA | https://app.crepc.sk/?fn=detailBiblioForm&sid=E17FC85307AF86FA3AC4D64547 |
| Characteristics of the output that is not registered in CRPA or CRAA | |
| OCA10. Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs | |
| OCA11. Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs | Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction |
| OCA12. Type of the output (if the output is not registered in CRPA or CRAA) | article |
| OCA13. Hyperlink to the webpage where the output is available (full text, other documentation, etc.) | |
| OCA14. Characteristics of the author's contribution | member of the international team |
| OCA15. Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. | The primary cause of heart failure is the loss of cardiomyocytes in the diseased adult heart. Previously, we reported that the miR-17-92 cluster plays a key role in cardiomyocyte proliferation. Here, we report that expression of miR-19a/19b, members of the miR-17-92 cluster, is induced in heart failure patients. We show that intra-cardiac injection of miR-19a/19b mimics enhances cardiomyocyte proliferation and stimulates cardiac regeneration in response to myocardial infarction (MI) injury. miR-19a/19b protected the adult heart in two distinctive phases: an early phase immediately after MI and long-term protection. Genome-wide transcriptome analysis demonstrates that genes related to the immune response are repressed by miR-19a/19b. Using an adeno-associated virus approach, we validate that miR-19a/19b reduces MI-induced cardiac damage and protects cardiac function. Finally, we confirm the therapeutic potential of miR-19a/19b in protecting cardiac function by systemically delivering miR-19a/19b into mice post-MI. Our study establishes miR-19a/19b as potential therapeutic targets to treat heart failure. |
| Other data | |
| OCA16. Annotation of the output in English | The primary cause of heart failure is the loss of cardiomyocytes in the diseased adult heart. Previously, we reported that the miR-17-92 cluster plays a key role in cardiomyocyte proliferation. Here, we report that expression of miR-19a/19b, members of the miR-17-92 cluster, is induced in heart failure patients. We show that intra-cardiac injection of miR-19a/19b mimics enhances cardiomyocyte proliferation and stimulates cardiac regeneration in response to myocardial infarction (MI) injury. miR-19a/19b protected the adult heart in two distinctive phases: an early phase immediately after MI and long-term protection. Genome-wide transcriptome analysis demonstrates that genes related to the immune response are repressed by miR-19a/19b. Using an adeno-associated virus approach, we validate that miR-19a/19b reduces MI-induced cardiac damage and protects cardiac function. Finally, we confirm the therapeutic potential of miR-19a/19b in protecting cardiac function by systemically delivering miR-19a/19b into mice post-MI. Our study establishes miR-19a/19b as potential therapeutic targets to treat heart failure. |
| OCA17. List of maximum 5 most significant citations corresponding to the output | 2024: Gui, L. - Jin, L. - Liu, H.: Cardiac regeneration: 20 years of development and update in zebrafish and mouse. In: All Life, vol. 17, no. 1, 2024, art. no. 2308904 -- SCI ; SCOPUS 2024: Wang, T., Chen, X., Wang, K., Ju, J., Yu, X., Yu, W., Liu, C., Wang, Y.: Cardiac regeneration: Preexisting cardiomyocyte as the hub of novel signaling pathway. In: Genes and Diseases, vol. 11, no. 2, 2024, s. 747-759 -- SCI ;SCOPUS 2024: Livkisa, D. - Chang, T.H. - Burnouf, T. - Czosseck, A. - Le, N.T.N. - Shamrin, G. - Yeh, W.T. - Kamimura, M. - Lundy, D.J.: Extracellular vesicles purified from serum-converted human platelet lysates offer strong protectionafter cardiac ischaemia/reperfusion injury. In: Biomaterials, vol. 306, 2024, art. no. 122502 -- SCOPUS 2024: Lu, W. - Liu, Z. - Chiara Villamil Orion, I.R. - Qu, Y. - Ma, G.: Inhibition of myocardial remodeling through miR-150/TET3 axis after AMI. In: Molecular Biology Reports, vol. 51, no. 1, 2024, art. no. 32 -- SCI ; SCOPUS 2024: Zheng, S. - Liu, T. - Chen, M. - Sun, F. - Fei, Y. - Chen, Y. - Tian, X. - Wu, Z. - Zhu, Z. - Zheng, W. - Wang, Y. - Wang, W.: Morroniside induces cardiomyocyte cell cycle activity and promotes cardiac repair after myocardialinfarction in adult rats. In: Frontiers in Pharmacology, vol. 14, 2024, art. no. 1260674 -- SCI ; SCOPUS |
| OCA18. Characteristics of the output's impact on socio-economic practice | contribution of new knowledge to the issue |
| OCA19. Characteristics of the output and related activities' impact on the educational process | research in the field |